Your browser doesn't support javascript.
loading
CRISPR/Cas9-based GLA knockout to generate the female Fabry disease human induced pluripotent stem cell line MHHi001-A-15.
Juchem, Malte; Lehmann, Nele; Behrens, Yvonne Lisa; Bär, Christian; Thum, Thomas; Hoepfner, Jeannine.
Afiliação
  • Juchem M; Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany; Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.
  • Lehmann N; Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany.
  • Behrens YL; Department of Human Genetics, Hannover Medical School, Hannover, Germany.
  • Bär C; Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany; Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany; Center of Translational Regenerative Medicine, Hannover Medical School, Hannover, Germany.
  • Thum T; Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany; Center of Translational Regenerative Medicine, Hannover Medical School, Hannover, Germany.
  • Hoepfner J; Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany. Electronic address: hoepfner.jeannine@mh-hannover.de.
Stem Cell Res ; 79: 103478, 2024 Jun 20.
Article em En | MEDLINE | ID: mdl-38905814
ABSTRACT
The X-linked lysosomal storage disorder Fabry disease originates from GLA gene mutations causing α-galactosidase A enzyme deficiency. Here we generated the GLA knockout hiPSC line MHHi001-A-15 (GLA-KOhiPSC) as an in vitro Fabry disease model by targeting exon 2 of the GLA gene by CRISPR/Cas9 in the established control hiPSC line MHHi001-A. GLA-KOhiPSCs retained the expression of pluripotency markers, trilineage differentiation potential, as well as normal karyotype and stem cell morphology but lacked α-galactosidase A enzyme activity. The GLA-KOhiPSCs represent a potent resource to not only study the Fabry disease manifestation but also screen for novel treatment options.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article